You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for New Drug Application (NDA): 217785


✉ Email this page to a colleague

« Back to Dashboard


NDA 217785 describes REZDIFFRA, which is a drug marketed by Madrigal and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the REZDIFFRA profile page.

The generic ingredient in REZDIFFRA is resmetirom. One supplier is listed for this compound. Additional details are available on the resmetirom profile page.
Summary for 217785
Tradename:REZDIFFRA
Applicant:Madrigal
Ingredient:resmetirom
Patents:5
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 217785
Generic Entry Date for 217785*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 217785
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REZDIFFRA resmetirom TABLET;ORAL 217785 NDA Madrigal Pharmaceuticals, Inc. 82576-060 82576-060-30 30 TABLET, COATED in 1 BOTTLE (82576-060-30)
REZDIFFRA resmetirom TABLET;ORAL 217785 NDA Madrigal Pharmaceuticals, Inc. 82576-080 82576-080-30 30 TABLET, COATED in 1 BOTTLE (82576-080-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength60MG
Approval Date:Mar 14, 2024TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 14, 2029
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Sign UpPatent Expiration:Sep 17, 2033Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
Patent:⤷  Sign UpPatent Expiration:Sep 17, 2033Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.